PURPOSE: In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings. METHODS: Prospective research cohort of patients initiating ART between April 2004 and April 2005 in Kampala, Uganda. The main endpoint was the substitution of at least 1 drug included in the initial combination. RESULTS: Five hundred Fifty-nine patients initiated on ART, 70% were female, median CD4+ count 98 (21-163) cells per microliter, median HIV RNA log₁₀ 5.4 (5.0-5.8). 413 (74%) patients were started on stavudine, lamivudine, and nevirapine, and 146 (36%) on zidovudine, lamivudine and efavirenz. One hundred Forty-eight (26.5%) had at least one treatment change (incidence rate 14.3 per 100 person-years; confidence interval: 12.2 to 16.9). The main reason for first treatment change was drug toxicity (n = 91, 61.5%). Stavudine accounted for the majority of the toxicities that led to drug substitution (n = 76, 84%). In the multivariate analysis, being female (P = 0.011) and being stage 3-4 as compared with 1-2 at ART initiation were predictive of stavudine substitution (P = 0.05). There was no difference in virologic outcome in patients who changed due to toxicity compared with those who did not. CONCLUSIONS: The majority of the treatment changes were due to stavudine-related toxicity. Long-term stavudine use is less well tolerated in women.
PURPOSE: In resource-limited settings, there are only a few antiretroviral treatment (ART) options. Our objective was to evaluate the reasons for first-line ART changes in resource-limited settings. METHODS: Prospective research cohort of patients initiating ART between April 2004 and April 2005 in Kampala, Uganda. The main endpoint was the substitution of at least 1 drug included in the initial combination. RESULTS: Five hundred Fifty-nine patients initiated on ART, 70% were female, median CD4+ count 98 (21-163) cells per microliter, median HIV RNA log₁₀ 5.4 (5.0-5.8). 413 (74%) patients were started on stavudine, lamivudine, and nevirapine, and 146 (36%) on zidovudine, lamivudine and efavirenz. One hundred Forty-eight (26.5%) had at least one treatment change (incidence rate 14.3 per 100 person-years; confidence interval: 12.2 to 16.9). The main reason for first treatment change was drug toxicity (n = 91, 61.5%). Stavudine accounted for the majority of the toxicities that led to drug substitution (n = 76, 84%). In the multivariate analysis, being female (P = 0.011) and being stage 3-4 as compared with 1-2 at ART initiation were predictive of stavudine substitution (P = 0.05). There was no difference in virologic outcome in patients who changed due to toxicity compared with those who did not. CONCLUSIONS: The majority of the treatment changes were due to stavudine-related toxicity. Long-term stavudine use is less well tolerated in women.
Authors: Cynthia Firnhaber; Laura M Smeaton; Beatriz Grinsztejn; Umesh Lalloo; Sharla Faesen; Wadzanai Samaneka; Rosa Infante; Aadia Rana; Nagalingeswaran Kumarasamy; James Hakim; Thomas B Campbell Journal: HIV Clin Trials Date: 2015-05-15
Authors: Christine J McGrath; Julia Njoroge; Grace C John-Stewart; Pamela K Kohler; Sarah F Benki-Nugent; Joan W Thiga; Anthony Etyang; Michael H Chung Journal: J Neurovirol Date: 2012-04-17 Impact factor: 2.643
Authors: A Sarah Walker; Andrew J Prendergast; Peter Mugyenyi; Paula Munderi; James Hakim; Addy Kekitiinwa; Elly Katabira; Charles F Gilks; Cissy Kityo; Patricia Nahirya-Ntege; Kusum Nathoo; Diana M Gibb Journal: Clin Infect Dis Date: 2012-09-12 Impact factor: 9.079
Authors: Shirin Heidari; Mirjam J Eckert; Susan Kippax; Quarraisha Abdool Karim; Papa Salif Sow; Mark A Wainberg Journal: J Int AIDS Soc Date: 2011-03-08 Impact factor: 5.396
Authors: Bernard Omech; Joseph Sempa; Barbara Castelnuovo; Kenneth Opio; Marcel Otim; Harriet Mayanja-Kizza; Robert Colebunders; Yukari C Manabe Journal: ISRN AIDS Date: 2012-08-23
Authors: Joep J van Oosterhout; Jane Mallewa; Symon Kaunda; Newton Chagoma; Yassin Njalale; Elizabeth Kampira; Mavuto Mukaka; Robert S Heyderman Journal: PLoS One Date: 2012-07-26 Impact factor: 3.240
Authors: Christine Njuguna; Catherine Orrell; Richard Kaplan; Linda-Gail Bekker; Robin Wood; Stephen D Lawn Journal: PLoS One Date: 2013-05-22 Impact factor: 3.240